{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:35:20Z","timestamp":1790357720904,"version":"4.1.0"},"reference-count":36,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2003,7,1]]},"abstract":"<jats:p> Purpose: To assess the neurocognitive effects of cranial radiotherapy on patients with low-grade gliomas, we analyzed cognitive performance data collected in a prospective, intergroup clinical trial. <\/jats:p><jats:p> Methods: Patients included 203 adults with supratentorial low-grade gliomas randomly assigned to a lower dose (50.4 Gy in 28 fractions) or a higher dose (64.8 Gy in 36 fractions) of localized radiotherapy. Folstein Mini-Mental State Examination (MMSE) scores and neurologic function scores (NFS) at baseline and key evaluations were analyzed. Median follow-up was 7.4 years in 101 patients still alive. A change of more than three MMSE points was considered clinically significant. <\/jats:p><jats:p> Results: In patients without tumor progression, significant deterioration from baseline occurred at years 1, 2, and 5 in 8.2%, 4.6%, and 5.3% of patients, respectively. Most patients with an abnormal baseline MMSE score (&lt; 27) experienced significant increases. Baseline variables such as radiation dose, conformal versus conventional radiotherapy, number of radiation fields, age, sex, tumor size, NFS, seizures, and seizure medications did not predict cognitive function changes. <\/jats:p><jats:p> Conclusion: In this population, most low-grade glioma patients maintained a stable neurocognitive status after focal radiotherapy as measured by the MMSE. Patients with an abnormal baseline MMSE were more likely to have an improvement in cognitive abilities than deterioration after receiving radiotherapy. Only a small percentage of patients had cognitive deterioration after radiotherapy. However, more discriminating neurocognitive assessment tools may identify cognitive decline not apparent with the use of the MMSE. <\/jats:p>","DOI":"10.1200\/jco.2003.04.172","type":"journal-article","created":{"date-parts":[[2003,6,30]],"date-time":"2003-06-30T19:58:12Z","timestamp":1057003092000},"page":"2519-2524","source":"Crossref","is-referenced-by-count":213,"title":["Effects of Radiotherapy on Cognitive Function in Patients With Low-Grade Glioma Measured by the Folstein Mini-Mental State Examination"],"prefix":"10.1200","volume":"21","author":[{"given":"Paul D.","family":"Brown","sequence":"first","affiliation":[{"name":"From the Mayo Clinic, Rochester, MN; Roger Maris Cancer Center, Fargo, ND; Radiation Therapy Oncology Group (RTOG) Operations Office, Philadelphia, PA; and Wake Forest University, School of Medicine, Winston-Salem, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan C.","family":"Buckner","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic, Rochester, MN; Roger Maris Cancer Center, Fargo, ND; Radiation Therapy Oncology Group (RTOG) Operations Office, Philadelphia, PA; and Wake Forest University, School of Medicine, Winston-Salem, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith R.","family":"O\u2019Fallon","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic, Rochester, MN; Roger Maris Cancer Center, Fargo, ND; Radiation Therapy Oncology Group (RTOG) Operations Office, Philadelphia, PA; and Wake Forest University, School of Medicine, Winston-Salem, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Iturria","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic, Rochester, MN; Roger Maris Cancer Center, Fargo, ND; Radiation Therapy Oncology Group (RTOG) Operations Office, Philadelphia, PA; and Wake Forest University, School of Medicine, Winston-Salem, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cerise A.","family":"Brown","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic, Rochester, MN; Roger Maris Cancer Center, Fargo, ND; Radiation Therapy Oncology Group (RTOG) Operations Office, Philadelphia, PA; and Wake Forest University, School of Medicine, Winston-Salem, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian P.","family":"O\u2019Neill","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic, Rochester, MN; Roger Maris Cancer Center, Fargo, ND; Radiation Therapy Oncology Group (RTOG) Operations Office, Philadelphia, PA; and Wake Forest University, School of Medicine, Winston-Salem, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd W.","family":"Scheithauer","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic, Rochester, MN; Roger Maris Cancer Center, Fargo, ND; Radiation Therapy Oncology Group (RTOG) Operations Office, Philadelphia, PA; and Wake Forest University, School of Medicine, Winston-Salem, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Dinapoli","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic, Rochester, MN; Roger Maris Cancer Center, Fargo, ND; Radiation Therapy Oncology Group (RTOG) Operations Office, Philadelphia, PA; and Wake Forest University, School of Medicine, Winston-Salem, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Arusell","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic, Rochester, MN; Roger Maris Cancer Center, Fargo, ND; Radiation Therapy Oncology Group (RTOG) Operations Office, Philadelphia, PA; and Wake Forest University, School of Medicine, Winston-Salem, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter J.","family":"Curran","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic, Rochester, MN; Roger Maris Cancer Center, Fargo, ND; Radiation Therapy Oncology Group (RTOG) Operations Office, Philadelphia, PA; and Wake Forest University, School of Medicine, Winston-Salem, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Abrams","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic, Rochester, MN; Roger Maris Cancer Center, Fargo, ND; Radiation Therapy Oncology Group (RTOG) Operations Office, Philadelphia, PA; and Wake Forest University, School of Medicine, Winston-Salem, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward G.","family":"Shaw","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic, Rochester, MN; Roger Maris Cancer Center, Fargo, ND; Radiation Therapy Oncology Group (RTOG) Operations Office, Philadelphia, PA; and Wake Forest University, School of Medicine, Winston-Salem, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01476278"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940401)73:7<1937::AID-CNCR2820730727>3.0.CO;2-G"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1227\/00006123-199304000-00010"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1987.67.2.0177"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1989.70.6.0853"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930701)72:1<190::AID-CNCR2820720134>3.0.CO;2-Y"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1294"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1016\/0090-3019(95)00184-0"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1097\/00006123-199605000-00002"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Bahary JP, Villemure JG, Choi S, et al: Low-grade pure and mixed cerebral astrocytomas treated in the CT scan era. J Neurooncol 27:173,1996\u2013177,","DOI":"10.1007\/BF00177481"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(96)00352-5"},{"key":"R12","unstructured":"Karim AB, Cornu P, Bleehen N, et al: Immediate postoperative radiotherapy in low grade glioma improves progression free survival but not overall survival: Preliminary results of an EORTC\/MRC randomized Phase III study. Proc Am Soc Clin Oncol 17:400a,1998,  (abstr 1544)"},{"key":"R13","unstructured":"Shaw E, Arusell, R, Scheithauer B, et al: A prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: Initial report of a NCCTG-RTOG-ECOG study (abstract). Proc Am Soc Clin Oncol 17:401a,1998,  (abstr 1545)"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.6.2195"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1992.tb01992.x"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.8.1225"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1990.00530010061020"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.4065\/71.9.829"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03500180078038"},{"key":"R21","unstructured":"Hammack J, Shaw E, Ivnik R, et al: Neurocognitive function in patients receiving radiation therapy (RT) for supratentorial low grade glioma (LGG): A North Central Cancer Treatment Group (NCCTG) prospective study. Proc Am Soc Clin Oncol 14:151,1995,  (abstr 299)"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(80)90175-3"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(81)90443-0"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1159\/000392816"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1093\/neurosurgery\/15.CN_suppl_1.301"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410360111"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(96)80015-0"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.39.6.789"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.10.1285"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(93)90183-V"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(96)91782-X"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(98)00268-8"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Hahn CA, Dunn RH, Logue PE, et al: A prospective study of neuropsychologic testing and quality of life assessment of adults with primary malignant CNS tumors. Int J Radiat Oncol Biol Phys 48:117,2000,  (suppl 13, abstr 117)","DOI":"10.1016\/S0360-3016(00)80030-9"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.2466\/pms.1987.65.1.64"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1987.00520210026014"},{"key":"R36","doi-asserted-by":"crossref","unstructured":"Zillmer EA, Fowler PC, Gutnick HN, et al: Comparison of two cognitive bedside screening instruments in nursing home residents: A factor analytic study. J Gerontol 45:P69,1990\u201374,","DOI":"10.1093\/geronj\/45.2.P69"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2003.04.172","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:28:20Z","timestamp":1653510500000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2003.04.172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7,1]]},"references-count":36,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2003,7,1]]}},"alternative-id":["10.1200\/JCO.2003.04.172"],"URL":"https:\/\/doi.org\/10.1200\/jco.2003.04.172","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7,1]]}}}